243 related articles for article (PubMed ID: 17327284)
21. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J
Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536
[TBL] [Abstract][Full Text] [Related]
22. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in the protein C gene as risk factor for venous thrombosis.
Pomp ER; Doggen CJ; Vos HL; Reitsma PH; Rosendaal FR
Thromb Haemost; 2009 Jan; 101(1):62-7. PubMed ID: 19132190
[TBL] [Abstract][Full Text] [Related]
24. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
[TBL] [Abstract][Full Text] [Related]
25. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
26. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms in the TAFI gene and the risk of venous thrombosis.
Kostka H; Kuhlisch E; Schellong S; Siegert G
Clin Lab; 2003; 49(11-12):645-7. PubMed ID: 14651335
[TBL] [Abstract][Full Text] [Related]
28. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
30. [Thrombotic microangiopathies].
Studt JD
Hamostaseologie; 2008 Dec; 28(5):358-64. PubMed ID: 19132166
[TBL] [Abstract][Full Text] [Related]
31. Factor IX-Padua enhances the fibrinolytic resistance of plasma clots.
Ammollo CT; Semeraro F; Colucci M; Simioni P
Thromb Haemost; 2014 Feb; 111(2):226-32. PubMed ID: 24136406
[TBL] [Abstract][Full Text] [Related]
32. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
33. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS).
Koster T; Rosendaal FR; Reitsma PH; van der Velden PA; Briët E; Vandenbroucke JP
Thromb Haemost; 1994 Jun; 71(6):719-22. PubMed ID: 7974338
[TBL] [Abstract][Full Text] [Related]
34. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
35. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
36. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Vairaktaris E; Yapijakis C; Nkenke E; Vassiliou S; Vylliotis A; Nixon AM; Derka S; Ragos V; Spyridonidou S; Tsigris C; Neukam FW; Patsouris E
Am J Hematol; 2007 Nov; 82(11):1010-2. PubMed ID: 17636471
[TBL] [Abstract][Full Text] [Related]
37. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
Sonmez M; Aydin K; Durmus A; Sucu N; Yilmaz M; Akdogan E; Koksal I; Ovali E; Omay SB
J Infect; 2007 Aug; 55(2):184-7. PubMed ID: 17418898
[TBL] [Abstract][Full Text] [Related]
38. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism.
Ay C; Jungbauer LV; Kaider A; Koder S; Panzer S; Pabinger I; Mannhalter C
Thromb Haemost; 2008 May; 99(5):899-904. PubMed ID: 18449419
[TBL] [Abstract][Full Text] [Related]
39. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience.
Douglas KW; Pollock KG; Young D; Catlow J; Green R
J Clin Apher; 2010; 25(2):47-53. PubMed ID: 20101677
[TBL] [Abstract][Full Text] [Related]
40. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
Alacacioğlu I; Ozcan MA; Alacacioğlu A; Polat M; Yüksel F; Demirkan F; Pişkin O; Ozgenç Y; Ozsan HG; Undar B
Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
